Skip to main content
Top
Published in: Endocrine 1/2023

06-05-2023 | Kidney Transplantation | Original Article

Postoperative fasting plasma glucose and family history diabetes mellitus can predict post-transplantation diabetes mellitus in kidney transplant recipients

Authors: Le Wang, Jin Huang, Yajuan Li, Kewei Shi, Sai Gao, Wangcheng Zhao, Shanshan Zhang, Chenguang Ding, Wei Gao

Published in: Endocrine | Issue 1/2023

Login to get access

Abstract

Purpose

To explore whether glycated albumin (GA) or fasting plasma glucose (FPG), both routinely monitored during patients’ hospital stay, can be used to predict post-transplantation diabetes mellitus (PTDM).

Methods

All kidney transplantation recipients (KTRs) from January 2017 to December 2018 were followed-up for 1 year. PTDM was diagnosed from day 45 post-operation to 1 year. When the completeness was above 80%, FPG or GA data on the day was selected, analyzed, and presented as range parameters and standard deviation (SD) and compared between PTDM and non-PTDM groups in fluctuation and stable periods. The predictive cut-off values were determined via receiver operating characteristic (ROC) analysis. The PTDM combined predictive mode, formed by the independent risk factors derived from logistic regression analyses, was compared with each independent risk factor with the independent ROC curve test.

Results

Among 536 KTRs, 38 patients developed PTDM up to 1 year post-operatively. The family history diabetes mellitus (OR, 3.21; P = 0.035), the FPG SD in fluctuation period >2.09 mmol/L (OR, 3.06; P = 0.002), and the FPG maximum in stable period >5.08 mmol/L (OR, 6.85; P < 0.001) were the PTDM independent risk factors. The discrimination of the combined mode (area under the curve = 0.81, sensitivity = 73.68%, and specificity = 76.31%) was higher than each prediction (P < 0.05).

Conclusions

The FPG standard deviation during the fluctuation period, FPG maximum during the stable period, and family history diabetes mellitus predicted PTDM with good discrimination and potential routine clinical use.
Appendix
Available only for authorised users
Literature
1.
go back to reference T. Dienemann, N. Fujii, Y. Li, S. Govani, N. Kosaraju, R.D. Bloom, H.I. Feldman, Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study. Transpl. Int. 29, 1017–1028 (2016)CrossRefPubMed T. Dienemann, N. Fujii, Y. Li, S. Govani, N. Kosaraju, R.D. Bloom, H.I. Feldman, Long-term patient survival and kidney allograft survival in post-transplant diabetes mellitus: a single-center retrospective study. Transpl. Int. 29, 1017–1028 (2016)CrossRefPubMed
2.
go back to reference M. Hecking, M. Haidinger, D. Döller, J. Werzowa, A. Tura, J. Zhang, M.D. Säemann, Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J. Am. Soc. Nephrol. 23, 739–749 (2012)CrossRefPubMedPubMedCentral M. Hecking, M. Haidinger, D. Döller, J. Werzowa, A. Tura, J. Zhang, M.D. Säemann, Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J. Am. Soc. Nephrol. 23, 739–749 (2012)CrossRefPubMedPubMedCentral
3.
go back to reference D.M. Zelle, E. Corpeleijn, J. Deinum, R.P. Stolk, R.O. Gans, G. Navis, S.J. Bakker, Pancreatic β-cell dysfunction and risk of new-onset diabetes after kidney transplantation. Diabetes Care. 36, 1926–1932 (2013)CrossRefPubMedPubMedCentral D.M. Zelle, E. Corpeleijn, J. Deinum, R.P. Stolk, R.O. Gans, G. Navis, S.J. Bakker, Pancreatic β-cell dysfunction and risk of new-onset diabetes after kidney transplantation. Diabetes Care. 36, 1926–1932 (2013)CrossRefPubMedPubMedCentral
4.
go back to reference T. Jenssen, A. Hartmann, Post-transplant diabetes mellitus in patients with solid organ transplants. Nat. Rev. Endocrinol. 15, 172–188 (2019)CrossRefPubMed T. Jenssen, A. Hartmann, Post-transplant diabetes mellitus in patients with solid organ transplants. Nat. Rev. Endocrinol. 15, 172–188 (2019)CrossRefPubMed
5.
go back to reference K. Tokodai, N. Amada, I. Haga, T. Takayama, A. Nakamura, The 5-time point oral glucose tolerance test as a predictor of new-onset diabetes after kidney transplantation. Diabetes Res. Clin. Pr. 103, 298–303 (2014)CrossRef K. Tokodai, N. Amada, I. Haga, T. Takayama, A. Nakamura, The 5-time point oral glucose tolerance test as a predictor of new-onset diabetes after kidney transplantation. Diabetes Res. Clin. Pr. 103, 298–303 (2014)CrossRef
6.
go back to reference S. Kesiraju, P. Paritala, U.M.R. Ch, S. Sahariah, New onset of diabetes after transplantation—an overview of epidemiology, mechanism of development and diagnosis. Transpl. Immunol. 30, 52–58 (2014)CrossRefPubMed S. Kesiraju, P. Paritala, U.M.R. Ch, S. Sahariah, New onset of diabetes after transplantation—an overview of epidemiology, mechanism of development and diagnosis. Transpl. Immunol. 30, 52–58 (2014)CrossRefPubMed
7.
go back to reference E. Dozio, V. Corradi, M. Proglio, E. Vianello, L. Menicanti, R. Rigolini, C. Ronco, Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). Diabetes Res. Clin. Pract. 140, 9–17 (2018)CrossRefPubMed E. Dozio, V. Corradi, M. Proglio, E. Vianello, L. Menicanti, R. Rigolini, C. Ronco, Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D). Diabetes Res. Clin. Pract. 140, 9–17 (2018)CrossRefPubMed
8.
go back to reference I.A. Eide, T.A.S. Halden, A. Hartmann, A. Asberg, D.O. Dahle, A.V. Reisaeter, T. Jenssen, Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria. Transpl. Int. 29, 568–578 (2016)CrossRefPubMed I.A. Eide, T.A.S. Halden, A. Hartmann, A. Asberg, D.O. Dahle, A.V. Reisaeter, T. Jenssen, Mortality risk in post-transplantation diabetes mellitus based on glucose and HbA1c diagnostic criteria. Transpl. Int. 29, 568–578 (2016)CrossRefPubMed
9.
go back to reference S. Takahashi, H. Uchino, T. Shimizu, A. Kanazawa, Y. Tamura, K. Sakai, Y. Tanaka, Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr. J. 54, 139–144 (2007)CrossRefPubMed S. Takahashi, H. Uchino, T. Shimizu, A. Kanazawa, Y. Tamura, K. Sakai, Y. Tanaka, Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr. J. 54, 139–144 (2007)CrossRefPubMed
10.
go back to reference A. Raghav, J. Ahmad, Glycated albumin in chronic kidney disease: pathophysiologic connections. Diabetes Metab. Syndr. 12, 463–468 (2018)CrossRefPubMed A. Raghav, J. Ahmad, Glycated albumin in chronic kidney disease: pathophysiologic connections. Diabetes Metab. Syndr. 12, 463–468 (2018)CrossRefPubMed
11.
go back to reference K. Neelofar, J. Ahmad, An overview of in vitro and in vivo glycation of albumin: a potential disease marker in diabetes mellitus. Glycoconj. J. 34, 575–584 (2017)CrossRefPubMed K. Neelofar, J. Ahmad, An overview of in vitro and in vivo glycation of albumin: a potential disease marker in diabetes mellitus. Glycoconj. J. 34, 575–584 (2017)CrossRefPubMed
12.
go back to reference J.M. Lu, L.N. Ji, Y.F. Li, Q.M. Li, S.S. Lin, X.F. Lv, Y. Gao, Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: a multicenter, prospective study. J. Diabetes Complicat. 30, 1609–1613 (2016)CrossRef J.M. Lu, L.N. Ji, Y.F. Li, Q.M. Li, S.S. Lin, X.F. Lv, Y. Gao, Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: a multicenter, prospective study. J. Diabetes Complicat. 30, 1609–1613 (2016)CrossRef
13.
go back to reference S. Bhat, M.G. Jagadeeshaprasad, V. Venkatasubramani, M.J. Kulkarni, Abundance matters: role of albumin in diabetes, a proteomics perspective. Expert Rev. Proteom. 14, 677–689 (2017)CrossRef S. Bhat, M.G. Jagadeeshaprasad, V. Venkatasubramani, M.J. Kulkarni, Abundance matters: role of albumin in diabetes, a proteomics perspective. Expert Rev. Proteom. 14, 677–689 (2017)CrossRef
14.
go back to reference N. Furusyo, T. Koga, M. Ai, S. Otokozawa, T. Kohzuma, H. Ikezaki, J. Hayashi, Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the kyushu and okinawa population study (KOPS). Diabetologia. 54, 3028–3036 (2011)CrossRefPubMed N. Furusyo, T. Koga, M. Ai, S. Otokozawa, T. Kohzuma, H. Ikezaki, J. Hayashi, Utility of glycated albumin for the diagnosis of diabetes mellitus in a Japanese population study: results from the kyushu and okinawa population study (KOPS). Diabetologia. 54, 3028–3036 (2011)CrossRefPubMed
15.
go back to reference A. Sinangil, V. Celik, S. Barlas, Y. Koc, T. Basturk, T. Sakaci, T. Ecder, The incidence of new onset diabetes after transplantation and related factors: single center experience. Nefrologia. 37, 181–188 (2017) CrossRefPubMed A. Sinangil, V. Celik, S. Barlas, Y. Koc, T. Basturk, T. Sakaci, T. Ecder, The incidence of new onset diabetes after transplantation and related factors: single center experience. Nefrologia. 37, 181–188 (2017) CrossRefPubMed
16.
go back to reference J. Werzowa, G. Pacini, M. Hecking, C. Fidler, M. Haidinger, H. Brath, A. Tura, Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitus. J. Diabetes Complic. 29, 1211–1216 (2015)CrossRef J. Werzowa, G. Pacini, M. Hecking, C. Fidler, M. Haidinger, H. Brath, A. Tura, Comparison of glycemic control and variability in patients with type 2 and posttransplantation diabetes mellitus. J. Diabetes Complic. 29, 1211–1216 (2015)CrossRef
17.
go back to reference H.Y. Jin, K. Lee, Y.J. Kim, T.S. Park, S. Lee, S.K. Park, H.C. Yu, The degree of hyperglycemia excursion in patients of kidney transplantation (KT) or liver transplantation (LT) assessed by continuous glucose monitoring (CGM): pilot study. J. Diabetes Res. 2019, 1–10 (2019) H.Y. Jin, K. Lee, Y.J. Kim, T.S. Park, S. Lee, S.K. Park, H.C. Yu, The degree of hyperglycemia excursion in patients of kidney transplantation (KT) or liver transplantation (LT) assessed by continuous glucose monitoring (CGM): pilot study. J. Diabetes Res. 2019, 1–10 (2019)
19.
go back to reference T.S. Joseph, Wu, M. Kagoli, J.J. Kaasboll, G.A. Bjune, Integrated disease surveillance and response (IDSR) in malawi: implementation gaps and challenges for timely alert. Plos One. 13, e0200858 (2018)CrossRef T.S. Joseph, Wu, M. Kagoli, J.J. Kaasboll, G.A. Bjune, Integrated disease surveillance and response (IDSR) in malawi: implementation gaps and challenges for timely alert. Plos One. 13, e0200858 (2018)CrossRef
20.
go back to reference A. Sharif, M. Hecking, A.P.J. De Vries, E. Porrini, M. Hornum, S. Rasoul-Rockenschaub, M.D. Säemann, Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am. J. Transpl. 14, 1992–2000 (2014)CrossRef A. Sharif, M. Hecking, A.P.J. De Vries, E. Porrini, M. Hornum, S. Rasoul-Rockenschaub, M.D. Säemann, Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am. J. Transpl. 14, 1992–2000 (2014)CrossRef
21.
go back to reference V. Shivaswamy, B. Boerner, J. Larsen, Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr. Rev. 37, 37–61 (2016)CrossRefPubMed V. Shivaswamy, B. Boerner, J. Larsen, Post-transplant diabetes mellitus: causes, treatment, and impact on outcomes. Endocr. Rev. 37, 37–61 (2016)CrossRefPubMed
22.
go back to reference M. Xia, H. Yang, X. Tong, H. Xie, F. Cui, W. Shuang, Risk factors for new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis. J. Diabetes Investig. 12, 109–122 (2020)CrossRefPubMedPubMedCentral M. Xia, H. Yang, X. Tong, H. Xie, F. Cui, W. Shuang, Risk factors for new-onset diabetes mellitus after kidney transplantation: a systematic review and meta-analysis. J. Diabetes Investig. 12, 109–122 (2020)CrossRefPubMedPubMedCentral
23.
go back to reference A. Sharif, S. Cohney, Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinol. 4, 337–349 (2016)CrossRefPubMed A. Sharif, S. Cohney, Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinol. 4, 337–349 (2016)CrossRefPubMed
24.
go back to reference D.D. De Lucena, J.R. De Sá, J.O. Medina-Pestana, E.B. Rangel, Modifiable variables are major risk factors for posttransplant diabetes mellitus in a time-dependent manner in kidney transplant: an observational cohort study. J. Diabetes Res. 2020, 1–10 (2020)CrossRef D.D. De Lucena, J.R. De Sá, J.O. Medina-Pestana, E.B. Rangel, Modifiable variables are major risk factors for posttransplant diabetes mellitus in a time-dependent manner in kidney transplant: an observational cohort study. J. Diabetes Res. 2020, 1–10 (2020)CrossRef
25.
go back to reference J. Xu, L. Xu, X. Wei, X. Li, M. Cai, Incidence and risk factors of posttransplantation dia betes mellitus in living donor kidney transplantation: a single-center retrospective study in China. Transpl. Proc. 50, 3381–3385 (2018)CrossRef J. Xu, L. Xu, X. Wei, X. Li, M. Cai, Incidence and risk factors of posttransplantation dia betes mellitus in living donor kidney transplantation: a single-center retrospective study in China. Transpl. Proc. 50, 3381–3385 (2018)CrossRef
26.
go back to reference R. Cai, M. Wu, Y. Xing, Pretransplant metabolic syndrome and its components predict post-transplantation diabetes mellitus in Chinese patients receiving a first renal transplant. Ther. Clin. Risk Manag. 15, 497–503 (2019)CrossRefPubMedPubMedCentral R. Cai, M. Wu, Y. Xing, Pretransplant metabolic syndrome and its components predict post-transplantation diabetes mellitus in Chinese patients receiving a first renal transplant. Ther. Clin. Risk Manag. 15, 497–503 (2019)CrossRefPubMedPubMedCentral
27.
go back to reference N.D. Bayer, P.T. Cochetti, M.S.A. Kumar, V. Teal, Y. Huan, C. Doria, S.E. Rosas, Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation. 90, 861–866 (2010) CrossRefPubMedPubMedCentral N.D. Bayer, P.T. Cochetti, M.S.A. Kumar, V. Teal, Y. Huan, C. Doria, S.E. Rosas, Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation. 90, 861–866 (2010) CrossRefPubMedPubMedCentral
28.
go back to reference T. Szili-Torok, W. Annema, J.L. Anderson, S.J. Bakker, U.J. Tietge, High density lipoprotein cholesterol efflux predicts incident new onset diabetes after transplantation (NODAT) in renal transplant recipients independent of high density lipoprotein cholesterol levels. Diabetes. 68, 1–32 (2019)CrossRef T. Szili-Torok, W. Annema, J.L. Anderson, S.J. Bakker, U.J. Tietge, High density lipoprotein cholesterol efflux predicts incident new onset diabetes after transplantation (NODAT) in renal transplant recipients independent of high density lipoprotein cholesterol levels. Diabetes. 68, 1–32 (2019)CrossRef
29.
go back to reference X. Lai, L. Zhang, J. Fang, G. Li, L. Xu, J. Ma, Z. Chen, OGTT 2-hour serum C-peptide index as a predictor of post-transplant diabetes mellitus in kidney transplant recipients. Ann. Transl. Med. 7, 538–546 (2019) CrossRefPubMedPubMedCentral X. Lai, L. Zhang, J. Fang, G. Li, L. Xu, J. Ma, Z. Chen, OGTT 2-hour serum C-peptide index as a predictor of post-transplant diabetes mellitus in kidney transplant recipients. Ann. Transl. Med. 7, 538–546 (2019) CrossRefPubMedPubMedCentral
30.
go back to reference X. He, L. Ying, X. Ma, Y. Shen, H. Su, J. Peng, W. Jia, An additional measurement of glycated albumin can help prevent missed diagnosis of diabetes in Chinese population. Clin. Chim. Acta. 475, 188–192 (2017)CrossRefPubMed X. He, L. Ying, X. Ma, Y. Shen, H. Su, J. Peng, W. Jia, An additional measurement of glycated albumin can help prevent missed diagnosis of diabetes in Chinese population. Clin. Chim. Acta. 475, 188–192 (2017)CrossRefPubMed
31.
go back to reference S. Sokooti, F. Klont, S.C. Tye, D. Kremer, R.M. Douwes, G. Hopfgartner, R.P.F. Dullaart, H.J.L. Heerspink, S.J.L. Bakker, Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients. Nephrol. Dial. Transpl. 37, 1375–1383 (2022)CrossRef S. Sokooti, F. Klont, S.C. Tye, D. Kremer, R.M. Douwes, G. Hopfgartner, R.P.F. Dullaart, H.J.L. Heerspink, S.J.L. Bakker, Association of diuretic use with increased risk for long-term post-transplantation diabetes mellitus in kidney transplant recipients. Nephrol. Dial. Transpl. 37, 1375–1383 (2022)CrossRef
32.
go back to reference J.B. Bang, C.K. Oh, Y.S. Kim, S.H. Kim, H.C. Yu, C.D. Kim, M.K. Ju, B.J. So, S.H. Lee, S.Y. Han, C.W. Jung, J.K. Kim, S.H. Lee, J.Y. Jeon, Insulin secretion and insulin resistance trajectories over 1 year after kidney transplantation: a multicenter prospective cohort study. Endocrinol. Metab. 35, 820–829 (2020)CrossRef J.B. Bang, C.K. Oh, Y.S. Kim, S.H. Kim, H.C. Yu, C.D. Kim, M.K. Ju, B.J. So, S.H. Lee, S.Y. Han, C.W. Jung, J.K. Kim, S.H. Lee, J.Y. Jeon, Insulin secretion and insulin resistance trajectories over 1 year after kidney transplantation: a multicenter prospective cohort study. Endocrinol. Metab. 35, 820–829 (2020)CrossRef
33.
go back to reference F. Cheng, Q. Li, J.L. Wang, Z.D. Wang, F. Zeng, Y. Zhang, Analysis of risk factors and establishment of a risk prediction model for post-transplant diabetes mellitus after kidney transplantation. Saudi Pharm. J. 30, 1088–1094 (2022)CrossRefPubMedPubMedCentral F. Cheng, Q. Li, J.L. Wang, Z.D. Wang, F. Zeng, Y. Zhang, Analysis of risk factors and establishment of a risk prediction model for post-transplant diabetes mellitus after kidney transplantation. Saudi Pharm. J. 30, 1088–1094 (2022)CrossRefPubMedPubMedCentral
Metadata
Title
Postoperative fasting plasma glucose and family history diabetes mellitus can predict post-transplantation diabetes mellitus in kidney transplant recipients
Authors
Le Wang
Jin Huang
Yajuan Li
Kewei Shi
Sai Gao
Wangcheng Zhao
Shanshan Zhang
Chenguang Ding
Wei Gao
Publication date
06-05-2023
Publisher
Springer US
Published in
Endocrine / Issue 1/2023
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-023-03374-y

Other articles of this Issue 1/2023

Endocrine 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine